There are no randomized trials to guide treatment in patients with IDH-wildtype low-grade gliomas, and these tumors are underrepresented in historical studies of low-grade glioma, including the RTOG 9802 trial reviewed above. The gene discussed is IDH1; the disease is central nervous system cancer.